MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-28-2026
OPKO Health Interest Expense 2011-2026 | OPK
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 207 M | -17 M | -156 M | 18.9 M | 12.7 M | -11.3 M | 1.54 M | 10.5 M | 3.9 M | 7.73 M | -3.09 M | 34.8 M | 164 K | 1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 207 M | -156 M | 7.92 M |
Quarterly Interest Expense OPKO Health
| 2026-Q1 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.71 M | -35.5 M | 4.85 M | 48.6 M | 58.9 M | 21.3 M | -11.6 M | -21.4 M | 3.39 M | - | 3.02 M | 3.08 M | -1.44 M | - | -3.36 M | -11.8 M | -927 K | - | 4.75 M | 18.2 M | -12.3 M | - | -15.5 M | -5.87 M | 977 K | - | -824 K | 8.58 M | 1.89 M | - | 597 K | -533 K | 3.04 M | - | -2.97 M | 5.97 M | 546 K | - | 17.5 M | 760 K | -1.51 M | - | -2.76 M | 2.99 M | 1.68 M | - | 1.87 M | 8.03 M | 2.33 M | - | 55 K | -266 K | 351 K | - | -671 K | -129 K | 87 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 58.9 M | -35.5 M | 2.05 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 17.1 | 0.56 % | $ 181 M |  China |
 |
CareDx, Inc
CDNA
|
524 K | $ 21.5 | 3.32 % | $ 1.15 B |  USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Agilent Technologies
A
|
81 M | $ 114.52 | -0.86 % | $ 34.8 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.55 | - | $ 2.06 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 24.81 | 1.31 % | $ 689 M | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Aspira Women's Health
AWH
|
1.81 M | - | -6.19 % | $ 10.5 M | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 14.13 | -6.98 % | $ 427 M | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 112.85 | -4.63 % | $ 9.31 B |  Irlanda |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 135.78 | 7.13 % | $ 21.6 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 85.5 | 1.04 % | $ 5.77 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.8 | 1.05 % | $ 444 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 9.44 | 1.94 % | $ 1.21 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 417.54 | -0.27 % | $ 12 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 17.41 | 5.77 % | $ 390 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 165.78 | -0.71 % | $ 8.22 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.16 | -0.87 % | $ 20 B |  Niderland |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | - | - | $ 19.8 B | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 87.6 | 0.6 % | $ 11 B | USA |
 |
Personalis
PSNL
|
24 K | $ 5.78 | 4.71 % | $ 342 M | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Interpace Biosciences
IDXG
|
-252 K | $ 2.12 | 7.07 % | $ 9.38 M | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 5.1 | -22.84 % | $ 213 M | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 52.87 | 0.09 % | $ 2.69 B | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 469.21 | -2.04 % | $ 177 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | - | - | $ 10.6 B | Niderland |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 60.4 | 3.34 % | $ 3.61 B | USA |
 |
Biomerica
BMRA
|
367 | $ 2.19 | 0.46 % | $ 5.03 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 255.84 | -0.37 % | $ 21.3 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 125.65 | 3.54 % | $ 5.88 B | USA |
 |
Natera
NTRA
|
9.32 M | $ 207.28 | 0.54 % | $ 20.4 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 9.53 | 1.38 % | $ 2.07 B | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
Waters Corporation
WAT
|
14.3 M | $ 307.12 | -0.68 % | $ 18.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 192.67 | -0.79 % | $ 21.4 B | USA |